Atrium Therapeutics corrects post-offering shares outstanding to 21,571,507
RNA•Atrium Therapeutics filed an amended 8-K correcting its post-offering share count to 21,571,507 common shares outstanding following the PIPE financing announced Oct. 7, 2026. The PIPE terms remain unchanged: 5,170,384 common shares sold and pre-funded warrants for up to 1,134,930 additional shares.
1. Corrected share count
Atrium Therapeutics filed an amended 8-K to correct its previously disclosed post-offering share count. The updated figure is 21,571,507 common shares outstanding following the PIPE financing announced Oct. 7, 2026; the financing terms are unchanged.
